Eight Capital - cantechletter.com https://www.cantechletter.com/2022/09/six-technology-and-cannabis-stocks-for-your-portfolio/
kneat.com
Eight Capital Rating: Buy
Target Price: $4.50
Projected one-year Return: 67 per cent
Software company kneat also fits in the offensive category but from the small cap perspective, according to Sgro and Kadve, since the company has captured just two per cent of a US$600 million total addressable market in the life sciences validation space, leaving plenty of room for growth.
“With eight of the world’s top ten life sciences companies now customers, we see Kneat’s model maturing with a focus on the “expand” leg of the growth phase. We think that this is making the rapid growth increasingly predictable. Importantly, we see this growth as resilient to any recessionary pressures, with customer expansion decisions driven by regulatory compliance and proven return on investment, not discretionary measures,” Sgro and Kadve said.